DE59210008D1 - Phagemid zum Screenen von Antikörpern - Google Patents

Phagemid zum Screenen von Antikörpern

Info

Publication number
DE59210008D1
DE59210008D1 DE59210008T DE59210008T DE59210008D1 DE 59210008 D1 DE59210008 D1 DE 59210008D1 DE 59210008 T DE59210008 T DE 59210008T DE 59210008 T DE59210008 T DE 59210008T DE 59210008 D1 DE59210008 D1 DE 59210008D1
Authority
DE
Germany
Prior art keywords
phagemid
screening antibodies
protease
encoding
phagemide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE59210008T
Other languages
English (en)
Inventor
Frank Dr Breitling
Melvyn Prof Dr Little
Stefan Dr Duebel
Michael Dr Braunagel
Iris Klewinghaus
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Deutsches Krebsforschungszentrum DKFZ
Original Assignee
Deutsches Krebsforschungszentrum DKFZ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=6435698&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE59210008(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Deutsches Krebsforschungszentrum DKFZ filed Critical Deutsches Krebsforschungszentrum DKFZ
Application granted granted Critical
Publication of DE59210008D1 publication Critical patent/DE59210008D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00—Libraries per se, e.g. arrays, mixtures
    • C40B40/02—Libraries contained in or displayed by microorganisms, e.g. bacteria or animal cells; Libraries contained in or displayed by vectors, e.g. plasmids; Libraries containing only microorganisms or vectors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1037—Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/10011—Details dsDNA Bacteriophages
    • C12N2795/10022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/10011—Details dsDNA Bacteriophages
    • C12N2795/10311—Siphoviridae
    • C12N2795/10322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
DE59210008T 1991-07-08 1992-07-06 Phagemid zum Screenen von Antikörpern Expired - Lifetime DE59210008D1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE4122599A DE4122599C2 (de) 1991-07-08 1991-07-08 Phagemid zum Screenen von Antikörpern

Publications (1)

Publication Number Publication Date
DE59210008D1 true DE59210008D1 (de) 2009-05-07

Family

ID=6435698

Family Applications (4)

Application Number Title Priority Date Filing Date
DE4122599A Expired - Lifetime DE4122599C2 (de) 1991-07-08 1991-07-08 Phagemid zum Screenen von Antikörpern
DE59210010T Expired - Lifetime DE59210010D1 (de) 1991-07-08 1992-07-06 Phagemid zum Screenen von Antikörpern
DE59209896T Revoked DE59209896D1 (de) 1991-07-08 1992-07-06 Phagemid zum screenen von antikörpern
DE59210008T Expired - Lifetime DE59210008D1 (de) 1991-07-08 1992-07-06 Phagemid zum Screenen von Antikörpern

Family Applications Before (3)

Application Number Title Priority Date Filing Date
DE4122599A Expired - Lifetime DE4122599C2 (de) 1991-07-08 1991-07-08 Phagemid zum Screenen von Antikörpern
DE59210010T Expired - Lifetime DE59210010D1 (de) 1991-07-08 1992-07-06 Phagemid zum Screenen von Antikörpern
DE59209896T Revoked DE59209896D1 (de) 1991-07-08 1992-07-06 Phagemid zum screenen von antikörpern

Country Status (8)

Country Link
US (5) US5849500A (de)
EP (3) EP2025753B1 (de)
JP (1) JPH06500930A (de)
AT (3) ATE481488T1 (de)
DE (4) DE4122599C2 (de)
DK (3) DK1065271T3 (de)
ES (2) ES2352818T3 (de)
WO (1) WO1993001288A1 (de)

Families Citing this family (602)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5821088A (en) * 1990-05-11 1998-10-13 Siga Pharmaceuticals, Inc. Use of gram-positive bacteria to express recombinant proteins
GB9015198D0 (en) * 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US6916605B1 (en) 1990-07-10 2005-07-12 Medical Research Council Methods for producing members of specific binding pairs
US6172197B1 (en) 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
DE4122599C2 (de) * 1991-07-08 1993-11-11 Deutsches Krebsforsch Phagemid zum Screenen von Antikörpern
PT1696031E (pt) * 1991-12-02 2010-06-25 Medical Res Council Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos
US6743929B1 (en) * 1992-08-25 2004-06-01 G. D. Searle & Co. Sulfonylalkanoylamino hydroxyethylamino sulfonamides useful as retroviral protease inhibitors
IT1270939B (it) * 1993-05-11 1997-05-26 Angeletti P Ist Richerche Bio Procedimento per la preparazione di immunogeni e reagenti diagnostici,e immunogeni e reagenti diagnostici cosi' ottenibili.
SE9304060D0 (sv) * 1993-12-06 1993-12-06 Bioinvent Int Ab Sätt att selektera specifika bakteriofager
US6576236B1 (en) 1994-07-01 2003-06-10 Dana Farber Cancer Institute Methods for stimulating T cell responses by manipulating a common cytokine receptor γ chain
EP0739981A1 (de) 1995-04-25 1996-10-30 Vrije Universiteit Brussel Variable Fragmente von Immunglobulinen-Verwendung zur therapeutischen oder veterinären Zwecken
US6090382A (en) 1996-02-09 2000-07-18 Basf Aktiengesellschaft Human antibodies that bind human TNFα
US5743909A (en) * 1996-06-24 1998-04-28 Collette; Michel Radiological method for preoperative determination of isometric attachment points of an ACL graft, surgical aiming instrument and method of use
PT975755E (pt) 1997-04-16 2007-06-26 Millennium Pharm Inc Proteínas crsp (proteínas segregadas ricas em cisteínas), moléculas de ácido nucleico que as codificam e suas utilizações
DE19752854C2 (de) * 1997-11-28 2000-07-06 Bundesrepublik Deutschland Let Zellspezifische retrovirale Vektoren mit Antikörperdomänen und Verfahren zu ihrer Herstellung für den selektiven Gentransfer
US7163682B2 (en) 1998-04-13 2007-01-16 The Forsyth Institute Glucan binding protein and glucosyltransferase immunogens
US7056517B2 (en) 1998-04-13 2006-06-06 The Forsyth Institute Glucosyltransferase immunogens
ES2299244T3 (es) * 1998-05-13 2008-05-16 Domantis Limited Sistema de exposicion de fagos para la seleccion de proteinas correctamente plegadas.
US6420110B1 (en) 1998-10-19 2002-07-16 Gpc Biotech, Inc. Methods and reagents for isolating biologically active peptides
EP1179000A4 (de) 1999-02-26 2005-10-12 Millennium Pharm Inc Ausscheidungsproteine und ihre verwendung
CA2669512A1 (en) 1999-03-25 2000-09-28 Abbott Gmbh & Co. Kg Human antibodies that bind human il-12 and methods for producing
DE19915057A1 (de) 1999-04-01 2000-10-19 Forschungszentrum Borstel Monoklonale Antikörper gegen das humane Mcm3 Protein, Verfahren zu ihrer Herstellung und ihre Verwendung
US6472147B1 (en) 1999-05-25 2002-10-29 The Scripps Research Institute Methods for display of heterodimeric proteins on filamentous phage using pVII and pIX, compositions, vectors and combinatorial libraries
US20040001826A1 (en) 1999-06-30 2004-01-01 Millennium Pharmaceuticals, Inc. Glycoprotein VI and uses thereof
US7291714B1 (en) 1999-06-30 2007-11-06 Millennium Pharmaceuticals, Inc. Glycoprotein VI and uses thereof
EP2360254A1 (de) 1999-08-23 2011-08-24 Dana-Farber Cancer Institute, Inc. Screeningverfahren zur Isolierung von Anti-pd1 Antikörper und deren Verwendungen
DE60034817T2 (de) 1999-12-30 2008-01-31 President And Fellows Of Harvard College, Cambridge Verfahren zur modulierung der aktivität von th2-zellen durch modulierung der aktivität von xbp-1
KR20120011898A (ko) * 2000-02-10 2012-02-08 아보트 러보러터리즈 사람 인터류킨-１８에 결합하는 항체 및 이를 제조하고 사용하는 방법
EP1714661A3 (de) 2000-05-19 2012-03-14 The Center for Blood Research, INC. Verfahren zur Diagnose und Behandlung von hämostatischen Störungen durch Modulation der P-Selectin Aktivität
WO2001093892A1 (en) 2000-06-08 2001-12-13 The Center For Blood Research, Inc. Methods and compositions for inhibiting immunoglobulin-mediated__reperfusion injury
AU2001273096B8 (en) 2000-06-28 2005-10-13 Dana-Farber Cancer Institute, Inc. PD-L2 molecules: novel PD-1 ligands and uses therefor
DE60143986D1 (de) 2000-07-14 2011-03-17 Cropdesign Nv Inhibitoren für cyclin-dependent-kinase von pflanzen
EP1339427A4 (de) 2000-11-01 2004-09-15 Elusys Therapeutics Inc Verfahren zur herstellung biospezifischer moleküle durch protein-transsplicing
WO2002044419A2 (en) 2000-11-28 2002-06-06 Wyeth Expression analysis of kiaa nucleic acids and polypeptides useful in the diagnosis and treatment of prostate cancer
US6821731B2 (en) 2000-11-28 2004-11-23 Wyeth Expression analysis of FKBP nucleic acids and polypeptides useful in the diagnosis of prostate cancer
AU2002231368C1 (en) 2001-01-05 2018-08-16 Amgen Fremont Inc. Antibodies to insulin-like growth factor I receptor
US7811768B2 (en) 2001-01-26 2010-10-12 Aviva Biosciences Corporation Microdevice containing photorecognizable coding patterns and methods of using and producing the same
US7015047B2 (en) * 2001-01-26 2006-03-21 Aviva Biosciences Corporation Microdevices having a preferential axis of magnetization and uses thereof
WO2008048300A2 (en) 2005-11-30 2008-04-24 Massachusetts Institute Of Technology Pathogen detection biosensor
EP2123749A3 (de) 2001-02-23 2010-02-24 DSM IP Assets B.V. Neuartige Gene zur Kodierung von neuartigen proteolytischen Enzymen
ATE497603T1 (de) 2001-03-02 2011-02-15 Gpc Biotech Ag Drei-hybrid-assaysystem
WO2002076196A1 (en) 2001-03-22 2002-10-03 Abbott Gmbh & Co. Kg Transgenic animals expressing antibodies specific for genes of interest and uses thereof
MXPA03008959A (es) 2001-04-02 2004-10-15 Wyeth Corp Pd-1, un receptor para b7-4 y sus usos.
EP1572868A4 (de) 2001-04-16 2007-04-04 Wyeth Corp Neue, polypeptidantigene codierende offene leseraster aus streptococcus pneumoniae und verwendungen davon
CA2385745C (en) 2001-06-08 2015-02-17 Abbott Laboratories (Bermuda) Ltd. Methods of administering anti-tnf.alpha. antibodies
BR0210593A (pt) 2001-06-22 2007-01-02 Pioneer Hi Bred Int polinucleotìdeos de defensina e métodos de uso
DE10135039C1 (de) * 2001-07-18 2003-03-13 Nemod Immuntherapie Ag Verfahren zur Isolierung großer Varianzen spezifischer Moleküle für ein Zielmolekül aus Phagemid-Gen-Bibliotheken
US6833441B2 (en) 2001-08-01 2004-12-21 Abmaxis, Inc. Compositions and methods for generating chimeric heteromultimers
US20040142325A1 (en) 2001-09-14 2004-07-22 Liat Mintz Methods and systems for annotating biomolecular sequences
US20040005709A1 (en) * 2001-10-24 2004-01-08 Hoogenboom Henricus Renerus Jacobus Mattheus Hybridization control of sequence variation
US7175983B2 (en) * 2001-11-02 2007-02-13 Abmaxis, Inc. Adapter-directed display systems
AR039067A1 (es) 2001-11-09 2005-02-09 Pfizer Prod Inc Anticuerpos para cd40
EP1458754B1 (de) 2001-12-18 2009-12-09 Endocube SAS Neue mit dem zelltod assoziierte proteine aus der thap familie und par4 verwandte signalwege, die bei der kontrolle von apoptosis involviert sind
US7858297B2 (en) 2001-12-18 2010-12-28 Centre National De La Recherche Scientifique Cnrs Chemokine-binding protein and methods of use
AU2002359721A1 (en) 2001-12-19 2003-07-09 Bristol-Myers Squibb Company Pichia pastoris formate dehydrogenase and uses therefor
EP1572149A2 (de) 2002-03-07 2005-09-14 The Forsyth Institute Immunogenität von glucan-bindungsprotein
US7214427B2 (en) * 2002-03-21 2007-05-08 Aviva Biosciences Corporation Composite beads comprising magnetizable substance and electro-conductive substance
US7745192B2 (en) 2002-04-03 2010-06-29 Venomics Pty Limited Prothrombin activating protein
US20030206898A1 (en) 2002-04-26 2003-11-06 Steven Fischkoff Use of anti-TNFalpha antibodies and another drug
ES2347550T3 (es) 2002-05-21 2010-11-02 Dsm Ip Assets B.V. Nuevas fosfolipasas y usos de las mismas.
WO2003106640A2 (en) * 2002-06-14 2003-12-24 Case Western Reserve University Cell targeting methods and compositions
USRE47770E1 (en) 2002-07-18 2019-12-17 Merus N.V. Recombinant production of mixtures of antibodies
PT2314629E (pt) 2002-07-18 2014-01-22 Merus B V Produção recombinante de misturas de anticorpos
KR20140058649A (ko) 2002-07-19 2014-05-14 애브비 바이오테크놀로지 리미티드 ＴＮＦα 관련 질환의 치료
US7250551B2 (en) 2002-07-24 2007-07-31 President And Fellows Of Harvard College Transgenic mice expressing inducible human p25
EA200500330A1 (ru) 2002-08-10 2006-06-30 Йейл Юниверсити Антагонисты nogo рецепторов
EP1530630A2 (de) 2002-08-19 2005-05-18 DSM IP Assets B.V. Neue lipasen und deren verwendung
AU2003250518A1 (en) 2002-08-20 2004-03-11 Yeda Research And Development Co. Ltd. Akap84 and its use for visualization of biological structures
KR20050058407A (ko) 2002-08-20 2005-06-16 밀레니엄 파머슈티컬스 인코퍼레이티드 자궁경부암의 확인, 평가, 예방 및 요법을 위한 조성물, 키트 및 방법
AU2003268486A1 (en) 2002-09-04 2004-03-29 Biopolymer Engineering, Inc. Cancer therapy using whole glucan particles and antibodies
US20050054054A1 (en) * 2002-11-12 2005-03-10 Foss Francine M. Interleukin-7 molecules with altered biological properties
AU2003302470A1 (en) * 2002-11-26 2004-06-18 Dyax Corporation Methods and compositions for controlling valency of phage display
PT1587907E (pt) 2003-01-07 2011-04-08 Dyax Corp Biblioteca de domínios de kunitz
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
US20040180387A1 (en) 2003-03-13 2004-09-16 Fujirebio Diagnostics, Inc. Detection of urinary mesothelin-/megakaryocyte potentiating factor-related peptides for assessment of ovarian cancer
US20050014932A1 (en) 2003-05-15 2005-01-20 Iogenetics, Llc Targeted biocides
US20100069614A1 (en) 2008-06-27 2010-03-18 Merus B.V. Antibody producing non-human mammals
ES2408582T3 (es) 2003-05-30 2013-06-21 Merus B.V. Biblioteca de Fab para la preparación de una mezcla de anticuerpos
EP2508608A1 (de) 2003-06-09 2012-10-10 Alnylam Pharmaceuticals Inc. Verfahren zur Behandlung neurodegenerativer Erkrankungen
HN2004000285A (es) 2003-08-04 2006-04-27 Pfizer Prod Inc ANTICUERPOS DIRIGIDOS A c-MET
AR045563A1 (es) 2003-09-10 2005-11-02 Warner Lambert Co Anticuerpos dirigidos a m-csf
US7799518B2 (en) 2003-10-07 2010-09-21 Millennium Pharmaceuticals, Inc. Nucleic acid molecules and proteins for the identification, assessment, prevention, and therapy of ovarian cancer
US20050100965A1 (en) 2003-11-12 2005-05-12 Tariq Ghayur IL-18 binding proteins
US7968684B2 (en) 2003-11-12 2011-06-28 Abbott Laboratories IL-18 binding proteins
MX350383B (es) 2004-01-09 2017-09-04 Pfizer Anticuerpos contra madcam.
EP1737971B1 (de) 2004-01-20 2017-08-16 Merus N.V. Gemische bindender proteine
EP2444805A3 (de) 2004-01-21 2012-06-20 Fujirebio America, Inc. Erkennung von Mesothelin-/Megakaryozyten zur Potenzierung von faktorbezogenen Peptiden in peritonealer Flüssigkeit zur Bewertung des Peritoneum und Peritonealhöhle
DE602005026260D1 (de) 2004-03-01 2011-03-24 Immune Disease Inst Inc Natürliche igm-antikörper und inhibitoren davon
US7157233B2 (en) 2004-03-24 2007-01-02 Tripath Imaging, Inc. Methods and compositions for the detection of cervical disease
TWI439284B (zh) 2004-04-09 2014-06-01 Abbvie Biotechnology Ltd 用於治療ＴＮＦα相關失調症之多重可變劑量療法
EP2527447A1 (de) 2004-06-03 2012-11-28 Athlomics Pty Ltd Mittel und Verfahren zur Diagnose von Stress
GB0414054D0 (en) 2004-06-23 2004-07-28 Owen Mumford Ltd Improvements relating to automatic injection devices
CA2573821A1 (en) 2004-07-16 2006-01-26 Pfizer Products Inc. Combination treatment for non-hematologic malignancies using an anti-igf-1r antibody
US7342093B2 (en) 2004-07-23 2008-03-11 University Of Massachusetts Compounds that inhibit Hsp90 protein-protein interactions with IAP proteins
EP1623996A1 (de) * 2004-08-06 2006-02-08 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Verbessertes Verfahren zur Auswahl eines Proteins von einer Bibliothek
GB0500417D0 (en) 2005-01-10 2005-02-16 Cambridge Antibody Tech Method of mutagenesis
JP5789073B2 (ja) * 2005-01-10 2015-10-07 メッドイミューン・リミテッド 変異誘発方法
GT200600031A (es) 2005-01-28 2006-08-29 Formulacion anticuerpo anti a beta
US7829673B2 (en) 2005-03-23 2010-11-09 Genmab A/S Antibodies against CD38 for treatment of multiple myeloma
AP2007004243A0 (en) 2005-04-25 2007-12-31 Pfizer Antibodies to myostatin
CA2604357C (en) 2005-04-26 2012-01-17 Pfizer Inc. P-cadherin antibodies
US7595380B2 (en) 2005-04-27 2009-09-29 Tripath Imaging, Inc. Monoclonal antibodies and methods for their use in the detection of cervical disease
CA2903138A1 (en) 2005-05-16 2006-11-23 Abbvie Biotechnology Ltd. Use of tnfa inhibitor for treatment of erosive polyarthritis
EP3263581B1 (de) 2005-05-17 2020-11-04 University of Connecticut Zusammensetzungen und verfahren zur immunmodulation in einem organismus
HUE030701T2 (hu) 2005-05-27 2017-05-29 Biogen Ma Inc Tweak-kötõ antitestek
EA201100177A1 (ru) 2005-06-17 2011-06-30 Элан Фарма Интернэшнл Лимитед СПОСОБЫ ОЧИСТКИ АНТИТЕЛ К β-АМИЛОИДУ
EP1907421A4 (de) 2005-06-30 2012-03-28 Abbott Lab Il-12/p40-bindende proteine
EP1910565A4 (de) 2005-07-07 2009-10-28 Athlomics Pty Ltd Polynukleotidmarkergene und deren expression zur diagnose von endotoxämie
GB2428293A (en) * 2005-07-13 2007-01-24 Domantis Ltd Phage display libraries
CN101253409A (zh) 2005-08-02 2008-08-27 埃克斯生物科技公司 使用IL-1α自身抗体诊断、治疗和预防血管疾病
SG2014010029A (en) 2005-08-19 2014-08-28 Abbott Lab Dual variable domain immunoglobin and uses thereof
US20070041905A1 (en) 2005-08-19 2007-02-22 Hoffman Rebecca S Method of treating depression using a TNF-alpha antibody
EP2500355A3 (de) 2005-08-19 2012-10-24 Abbott Laboratories Immunglobuline mit zweifacher variabler Domäne und ihre Verwendung
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
AU2006297571B2 (en) 2005-09-07 2012-03-15 Amgen Fremont Inc. Human monoclonal antibodies to activin receptor-like kinase-1
US8906864B2 (en) 2005-09-30 2014-12-09 AbbVie Deutschland GmbH & Co. KG Binding domains of proteins of the repulsive guidance molecule (RGM) protein family and functional fragments thereof, and their use
WO2007050793A2 (en) 2005-10-25 2007-05-03 The Johns Hopkins University Methods and compositions for the treatment of marfan syndrome and associated disorders
AU2006337105B2 (en) 2005-11-01 2013-05-02 Abbvie Biotechnology Ltd Methods and compositions for diagnosing ankylosing spondylitis using biomarkers
ATE547709T1 (de) 2005-11-14 2012-03-15 Metamol Theranostics Llc Tumorinvasionsfördernde peptidsequenz
AU2006319358B2 (en) 2005-11-30 2012-01-19 AbbVie Deutschland GmbH & Co. KG Anti-Abeta globulomer antibodies, antigen-binding moieties thereof, corresponding hybridomas, nucleic acids, vectors, host cells, methods of producing said antibodies, compositions comprising said antibodies, uses of said antibodies and methods of using said antibodies
RS53270B2 (sr) 2005-11-30 2018-05-31 Abbvie Deutschland Monoklonalna antitela protiv amiloidnog beta proteina i njihova upotreba
US20070264687A1 (en) 2005-12-15 2007-11-15 Min-Yuan Chou Recombinant triplex scaffold-based polypeptides
US10183986B2 (en) 2005-12-15 2019-01-22 Industrial Technology Research Institute Trimeric collagen scaffold antibodies
US8014957B2 (en) 2005-12-15 2011-09-06 Fred Hutchinson Cancer Research Center Genes associated with progression and response in chronic myeloid leukemia and uses thereof
US7632498B2 (en) 2005-12-19 2009-12-15 Tripath Imaging, Inc. MCM6 and MCM7 monoclonal antibodies and methods for their use in the detection of cervical disease
WO2007090076A2 (en) 2006-01-27 2007-08-09 Tripath Imaging, Inc. Methods for identifying patients with an increased likelihood of having ovarian cancer and compositions therefor
JP5829373B2 (ja) 2006-01-27 2015-12-09 バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎ ＭＡ Ｉｎｃ． Ｎｏｇｏレセプターアンタゴニスト
TWI417301B (zh) 2006-02-21 2013-12-01 Wyeth Corp 對抗人類介白素-２２（ｉｌ-２２）之抗體及其用途
TW200744634A (en) 2006-02-21 2007-12-16 Wyeth Corp Methods of using antibodies against human IL-22
EP2010677A4 (de) * 2006-02-24 2010-04-14 Investigen Inc Verfahren und zusammensetzungen zum nachweis von polynukleotiden
WO2007111661A2 (en) 2006-03-20 2007-10-04 Xoma Technology Ltd. Human antibodies specific for gastrin materials and methods
KR20150006085A (ko) 2006-04-05 2015-01-15 애브비 바이오테크놀로지 리미티드 항체 정제
CA2564435A1 (en) 2006-04-10 2007-10-10 Abbott Biotechnology Ltd. Methods for monitoring and treating intestinal disorders
EP2666472A3 (de) 2006-04-10 2014-04-02 Abbott Biotechnology Ltd Anwendungen und Zusammensetzungen zur Behandlung von Psoriasis-Arthritis
EP2703010A3 (de) 2006-04-10 2014-08-06 AbbVie Biotechnology Ltd Anwendungen und Zusammensetzungen zur Behandlung von rheumatoider Arthritis
US10522240B2 (en) 2006-05-03 2019-12-31 Population Bio, Inc. Evaluating genetic disorders
US7702468B2 (en) 2006-05-03 2010-04-20 Population Diagnostics, Inc. Evaluating genetic disorders
CA2651992A1 (en) 2006-06-30 2008-01-10 Abbott Biotechnology Ltd. Automatic injection device
JP4546578B2 (ja) 2006-07-05 2010-09-15 カタリスト・バイオサイエンシーズ・インコーポレイテッド プロテアーゼスクリーニング方法およびそれにより同定されるプロテアーゼ
ES2613957T3 (es) 2006-08-04 2017-05-29 Medimmune Limited Anticuerpos contra ERBB2
MY188368A (en) 2006-09-08 2021-12-06 Abbott Lab Interleukin-13 binding proteins
HUE044136T2 (hu) 2006-09-26 2019-09-30 Genmab As Anti-CD38 plusz kortikoszteroidok plusz nem-kortikoszteroid kemoterápiás szer daganatok kezelésére
JP2010506839A (ja) 2006-10-12 2010-03-04 ワイス エルエルシー 乳光の低減を伴う方法および組成物
US20080096193A1 (en) * 2006-10-24 2008-04-24 Charles Robert Bupp Methods and compositions for detecting polynucleotides
CA2666317C (en) 2006-11-03 2013-08-06 Wyeth Glycolysis-inhibiting substances in cell culture
AU2007323799B2 (en) 2006-11-15 2013-07-18 Eli Lilly And Company Anti-TSG101 antibodies and their uses for treatment of viral infections
US7488807B2 (en) 2006-11-22 2009-02-10 3M Innovative Properties Company Antibody with protein A selectivity
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
DK2121979T3 (en) 2006-12-05 2017-09-25 Decode Genetics Ehf Genetic markers for risk management of cardiac arrhythmia
WO2008077145A2 (en) 2006-12-20 2008-06-26 Xoma Technology Ltd. Treatment of il-1-beta related diseases
NZ619576A (en) 2006-12-27 2014-07-25 Harvard College Compositions and methods for the treatment of infections and tumors
KR20150038227A (ko) 2007-01-16 2015-04-08 애브비 인코포레이티드 건선의 치료방법
EP2111553B1 (de) 2007-01-24 2018-09-19 Carnegie Mellon University Optische biosensoren
JP2010520745A (ja) 2007-02-07 2010-06-17 デコード・ジェネティクス・イーエイチエフ 前立腺癌のリスクに寄与する遺伝子変異体
JP5646179B2 (ja) 2007-02-21 2014-12-24 デコード・ジェネティクス・イーエイチエフ 循環器疾患に関連する遺伝的感受性変異体
US7771947B2 (en) * 2007-02-23 2010-08-10 Investigen, Inc. Methods and compositions for rapid light-activated isolation and detection of analytes
EP2486928A1 (de) 2007-02-27 2012-08-15 Abbott GmbH & Co. KG Verfahren zur Behandlung von Amyloidosen
JP4842400B2 (ja) 2007-03-22 2011-12-21 ヘプテアズ・セラピューティクス・リミテッド Ｇタンパク質共役型受容体変異体及びその選択方法
WO2008123999A2 (en) 2007-04-02 2008-10-16 Amgen Fremont Inc. Anti-ige antibodies
RU2571931C2 (ru) 2007-04-13 2015-12-27 Каталист Биосайенсис, Инк. Полипептиды на основе модифицированного фактора vii и их применение
MX2009012722A (es) 2007-05-25 2009-12-11 Decode Genetics Ehf Variantes geneticas sobre chr 5p12 y 10q26 como marcadores para el uso en la evaluacion del riesgo, diagnostico, pronostico y tratamiento del cancer de mama.
US8999337B2 (en) 2007-06-11 2015-04-07 Abbvie Biotechnology Ltd. Methods for treating juvenile idiopathic arthritis by inhibition of TNFα
PL2170956T3 (pl) 2007-06-15 2015-04-30 Deutsches Krebsforschungszentrum Stiftung Des Oeffentlichen Rechts Leczenie nowotworów z zastosowaniem specyficznego przeciwciała anty-L1
US8697360B2 (en) 2007-11-30 2014-04-15 Decode Genetics Ehf. Genetic variants on CHR 11Q and 6Q as markers for prostate and colorectal cancer predisposition
WO2009079212A2 (en) 2007-12-03 2009-06-25 Carnegie Mellon University Linked peptide fluorogenic biosensors
GB0724051D0 (en) 2007-12-08 2008-01-16 Medical Res Council Mutant proteins and methods for producing them
PL2391650T3 (pl) 2007-12-20 2015-03-31 Xoma Us Llc Sposoby leczenia dny
GB0724860D0 (en) 2007-12-20 2008-01-30 Heptares Therapeutics Ltd Screening
CN102016059B (zh) 2007-12-28 2014-10-22 依兰制药公司 淀粉样变性的治疗和预防
GB0802474D0 (en) 2008-02-11 2008-03-19 Heptares Therapeutics Ltd Mutant proteins and methods for selecting them
CA2714521A1 (en) 2008-02-14 2009-08-20 Decode Genetics Ehf Susceptibility variants for lung cancer
AU2009219358A1 (en) 2008-02-28 2009-09-03 3M Innovative Properties Company Antibodies to Clostridium difficile spores and uses thereof
US8962803B2 (en) 2008-02-29 2015-02-24 AbbVie Deutschland GmbH & Co. KG Antibodies against the RGM A protein and uses thereof
BRPI0908715A2 (pt) 2008-03-18 2016-05-03 Abbott Lab métodos para tratamento da psoríase
CA2724666A1 (en) 2008-04-01 2009-10-08 Decode Genetics Ehf Susceptibility variants for peripheral arterial disease and abdominal aortic aneurysm
KR101634719B1 (ko) 2008-04-25 2016-06-29 다이액스 코포레이션 Ｆｃｒｎ에 대한 항체 및 이들의 용도
EP2282769A4 (de) 2008-04-29 2012-04-25 Abbott Lab Dual-variable- domain-immunglobuline und ihre verwendungen
US20100260668A1 (en) * 2008-04-29 2010-10-14 Abbott Laboratories Dual Variable Domain Immunoglobulins and Uses Thereof
ES2579554T3 (es) 2008-05-09 2016-08-12 Abbvie Deutschland Gmbh & Co Kg Anticuerpos para el receptor de productos terminales de glicación avanzada (RAGE) y usos de los mismos
RU2010153580A (ru) 2008-06-03 2012-07-20 Эбботт Лэборетриз (Us) Иммуноглобулины с двумя вариабельными доменами и их применение
CA2725666A1 (en) 2008-06-03 2009-12-10 Abbott Laboratories Dual variable domain immunoglobulins and uses thereof
CA2729934A1 (en) 2008-07-07 2010-01-14 Decode Genetics Ehf Genetic variants for breast cancer risk assessment
CN104829718A (zh) 2008-07-08 2015-08-12 艾伯维公司 前列腺素e2结合蛋白及其用途
JP5674654B2 (ja) 2008-07-08 2015-02-25 アッヴィ・インコーポレイテッド プロスタグランジンｅ２二重可変ドメイン免疫グロブリンおよびその使用
US8058406B2 (en) 2008-07-09 2011-11-15 Biogen Idec Ma Inc. Composition comprising antibodies to LINGO or fragments thereof
WO2010025050A2 (en) * 2008-08-28 2010-03-04 The Uab Research Foundation Affecting bone related conditions using cd68 blocking agents
CA3073384A1 (en) 2008-09-05 2010-03-11 President And Fellows Of Harvard College Continuous directed evolution of proteins and nucleic acids
WO2010033237A2 (en) * 2008-09-22 2010-03-25 Calmune Corporation Methods for creating diversity in libraries and libraries, display vectors and methods, and displayed molecules
WO2010033229A2 (en) * 2008-09-22 2010-03-25 Calmune Corporation Methods and vectors for display of molecules and displayed molecules and collections
EP2344180A2 (de) 2008-09-23 2011-07-20 Wyeth LLC Verfahren zur vorhersage der produktion von aktivierenden signalen durch vernetzende bindungsproteine
US20110287026A1 (en) 2008-09-23 2011-11-24 President And Fellows Of Harvard College Sirt4 and uses thereof
EP3530672A1 (de) 2008-09-26 2019-08-28 Dana Farber Cancer Institute, Inc. Menschliche anti-pd1-, pd-l1- und pd-l2-antikörper und verwendungen davon
JP2012503982A (ja) 2008-09-26 2012-02-16 ワイス・エルエルシー 適合性ディスプレイベクター系
TR201802130T4 (tr) 2008-10-10 2018-03-21 Beth Israel Deaconess Medical Ct Inc Biyokimyasal olarak stabilize edilmiş HIV-1 env trimer aşısı.
EP2349329A4 (de) 2008-10-14 2012-10-31 Dyax Corp Verwendung von igf-ii/igf-iie-bindung zur behandlung und prävention von systemischer sklerose im zusammenhang mit lungenfibrose
TW201024318A (en) 2008-10-20 2010-07-01 Abbott Lab Isolation and purification of antibodies using protein A affinity chromatography
DK3199553T3 (da) 2008-10-29 2019-07-22 Circular Commitment Company Fremgangsmåder og midler til diagnosticering og behandling af hepatocellulært carcinom
AR073997A1 (es) 2008-10-29 2010-12-15 Wyeth Corp Formulaciones de moleculas de union a antigeno de dominio unico. metodo. kit
CA2739352C (en) 2008-10-29 2021-07-13 Wyeth Llc Methods for purification of single domain antigen binding molecules
EP2361093A2 (de) 2008-11-26 2011-08-31 Five Prime Therapeutics, Inc. Zusammensetzungen und verfahren zur regulierung der expression von kollagen und glattem muskel-actin durch serpin2
CN102282265B (zh) 2008-11-28 2020-07-24 埃默里大学 用于治疗传染病和肿瘤的方法
MX2011005953A (es) * 2008-12-04 2011-08-17 Abbott Lab Inmunoglobulinas de dominio variable dual y usos de las mismas.
US9181315B2 (en) 2009-01-08 2015-11-10 Dana-Farber Cancer Institute, Inc. Compositions and methods for induced brown fat differentiation
US9249306B2 (en) 2009-02-18 2016-02-02 Carnegie Mellon University Quenched dendrimeric dyes for florescence detection
US8030026B2 (en) 2009-02-24 2011-10-04 Abbott Laboratories Antibodies to troponin I and methods of use thereof
US8835610B2 (en) 2009-03-05 2014-09-16 Abbvie Inc. IL-17 binding proteins
EP2403880A1 (de) 2009-03-05 2012-01-11 Tripath Imaging, Inc. Monoklonale antikörper gegen matrixmetalloproteinase-7 (mmp-7) und verfahren zu ihrer verwendung beim nachweis von eierstockkrebs
AU2010221188A1 (en) 2009-03-06 2011-10-20 Tripath Imaging, Inc. Glycodelin monoclonal antibodies and methods for their use in the detection of ovarian cancer
CN102449165B (zh) 2009-04-03 2014-07-09 解码遗传学私营有限责任公司 用于心房颤动和中风的风险管理的遗传标志
BRPI1012162A2 (pt) 2009-04-29 2016-01-12 Abbott Biotech Ltd dispositivo de injeção automática
WO2010126972A1 (en) 2009-04-29 2010-11-04 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Erg monoclonal antibodies
JP5797642B2 (ja) * 2009-05-20 2015-10-21 ノビミューン エスアー 合成ポリペプチドライブラリーおよび天然で多様化されたポリペプチドバリアントを作製するための方法
EP2261242A1 (de) 2009-06-10 2010-12-15 Universite Catholique De Louvain Aspartat-N-Acetyltransferaseenzym, Diagnoseverfahren und therapeutisches Verfahren
GB0910725D0 (en) 2009-06-22 2009-08-05 Heptares Therapeutics Ltd Mutant proteins and methods for producing them
EP2272979A1 (de) 2009-06-30 2011-01-12 Centre National de la Recherche Scientifique (CNRS) Verfahren zum Testen einer Person, die eine Prädisposition für Krebs aufzuweisen scheint
CN102481380A (zh) 2009-07-09 2012-05-30 霍夫曼-拉罗奇有限公司 体内肿瘤血管系统成像
EP2451977A4 (de) 2009-07-10 2013-01-02 Decode Genetics Ehf Genetische marker für das risiko von diabetes mellitus
TW201109438A (en) * 2009-07-29 2011-03-16 Abbott Lab Dual variable domain immunoglobulins and uses thereof
EP2287336A1 (de) 2009-07-31 2011-02-23 Exhonit Therapeutics SA Verfahren und Methoden zur Alzheimer-Diagnose
WO2011014771A1 (en) 2009-07-31 2011-02-03 Wayne State University Monophosphorylated lipid a derivatives
US9259476B2 (en) 2009-07-31 2016-02-16 Wayne State University Monophosphorylated lipid A derivatives
PE20121647A1 (es) 2009-08-29 2012-12-31 Abbvie Inc Proteinas terapeuticas de union a dll4
TW201119673A (en) 2009-09-01 2011-06-16 Abbott Lab Dual variable domain immunoglobulins and uses thereof
US20110189183A1 (en) 2009-09-18 2011-08-04 Robert Anthony Williamson Antibodies against candida, collections thereof and methods of use
US8926976B2 (en) 2009-09-25 2015-01-06 Xoma Technology Ltd. Modulators
AU2010298036B2 (en) 2009-09-25 2015-05-21 Xoma Technology Ltd. Screening methods
WO2011038290A2 (en) 2009-09-25 2011-03-31 The U. S. A., As Represented By The Secretary, Department Of Health And Human Services Neutralizing antibodies to hiv-1 and their use
CN102639700A (zh) 2009-09-30 2012-08-15 哈佛大学校长及研究员协会 通过调节自噬增强基因产物调节自噬的方法
TW201119676A (en) 2009-10-15 2011-06-16 Abbott Lab Dual variable domain immunoglobulins and uses thereof
BR112012009289B8 (pt) 2009-10-20 2021-05-25 Abbott Laboratoires método para purificar um anticorpo anti-il-13 a partir de uma mistura de amostra que compreende um anticorpo anti-il-13 e pelo menos uma proteína de célula hospedeira (hcp)
US20110098862A1 (en) 2009-10-27 2011-04-28 ExxonMobil Research Engineering Company Law Department Multi-stage processes and control thereof
UY32979A (es) 2009-10-28 2011-02-28 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
WO2011053707A1 (en) 2009-10-31 2011-05-05 Abbott Laboratories Antibodies to receptor for advanced glycation end products (rage) and uses thereof
US9244063B2 (en) 2009-11-11 2016-01-26 Gentian As Immunoassay for assessing related analytes of different origin
WO2011060272A2 (en) 2009-11-13 2011-05-19 Dana-Farber Cancer Institute, Inc. Compositions, kits, and methods for the diagnosis, prognosis, monitoring, treatment and modulation of post-transplant lymphoproliferative disorders and hypoxia associated angiogenesis disorders using galectin-1
EP2325311A1 (de) 2009-11-18 2011-05-25 Pierre Fabre Medicament Neuer Phagenanzeigevektor
CA2780069C (en) 2009-12-08 2018-07-17 Abbott Gmbh & Co. Kg Monoclonal antibodies against the rgm a protein for use in the treatment of retinal nerve fiber layer degeneration
WO2011085103A2 (en) 2010-01-06 2011-07-14 Dyax Corp. Plasma kallikrein binding proteins
WO2011088163A1 (en) 2010-01-14 2011-07-21 President And Fellows Of Harvard College Methods for modulating skeletal remodeling and patterning by modulating shn2 activity, shn3 activity, or shn2 and shn3 activity in combination
US10429384B2 (en) 2010-01-22 2019-10-01 Dana-Farber Cancer Institute, Inc. Compositions, kits, and methods for identification, assessment, prevention, and therapy of metabolic disorders
CA2789168A1 (en) 2010-02-02 2011-08-11 Abbott Biotechnology Ltd. Methods and compositions for predicting responsiveness to treatment with tnf-.alpha. inhibitor
TWI518325B (zh) 2010-02-04 2016-01-21 自治醫科大學 對ａｌｋ抑制劑具有先抗性或後抗性癌症的識別、判斷和治療
SG10201501562VA (en) 2010-03-02 2015-04-29 Abbvie Inc Therapeutic dll4 binding proteins
US10706955B2 (en) 2010-03-23 2020-07-07 Iogenetics, Llc Bioinformatic processes for determination of peptide binding
MX336196B (es) 2010-04-15 2016-01-11 Abbvie Inc Proteinas de union a amiloide beta.
HUE033063T2 (hu) 2010-05-14 2017-11-28 Abbvie Inc IL-1 kötõ fehérjék
EP2577309B1 (de) 2010-05-25 2016-11-23 Carnegie Mellon University Gezielte sonden für zellphysiologie
EP2575884B1 (de) 2010-06-03 2018-07-18 AbbVie Biotechnology Ltd Anwendungen und zusammensetzungen zur behandlung von acne inversa
SG186302A1 (en) 2010-06-16 2013-02-28 Abbott Lab Comparison of protein samples
US20120009196A1 (en) 2010-07-08 2012-01-12 Abbott Laboratories Monoclonal antibodies against hepatitis c virus core protein
UY33492A (es) 2010-07-09 2012-01-31 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
WO2012007880A2 (en) 2010-07-16 2012-01-19 Ablynx Nv Modified single domain antigen binding molecules and uses thereof
WO2012018387A2 (en) 2010-08-02 2012-02-09 Population Diagnotics, Inc. Compositions and methods for discovery of causative mutations in genetic disorders
CA2807014A1 (en) 2010-08-03 2012-02-09 Abbvie Inc. Dual variable domain immunoglobulins and uses thereof
WO2012019061A2 (en) 2010-08-05 2012-02-09 Stem Centrx, Inc. Novel effectors and methods of use
EP2420250A1 (de) 2010-08-13 2012-02-22 Universitätsklinikum Münster Anti-Syndecan-4-Antikörper
WO2012024187A1 (en) 2010-08-14 2012-02-23 Abbott Laboratories Amyloid-beta binding proteins
US9505829B2 (en) 2010-08-19 2016-11-29 Zoetis Belgium S.A. Anti-NGF antibodies and their use
CA2809433A1 (en) 2010-08-26 2012-03-01 Abbvie Inc. Dual variable domain immunoglobulins and uses thereof
MX2013002255A (es) 2010-08-27 2013-07-03 Stem Centrx Inc Moduladores de proteina de notum y metodos de uso.
CA2810016A1 (en) 2010-09-03 2012-03-08 Stem Centrx, Inc. Novel modulators and methods of use
CA2810909A1 (en) 2010-09-20 2012-03-29 Abbvie Inc. Purification of antibodies using simulated moving bed chromatography
US9005907B2 (en) 2010-10-01 2015-04-14 St. Jude Children's Research Hospital Methods and compositions for typing molecular subgroups of medulloblastoma
WO2012052391A1 (en) 2010-10-19 2012-04-26 Glaxo Group Limited Polypeptide with jmjd3 catalytic activity
US9072766B2 (en) 2010-11-18 2015-07-07 Beth Israel Deaconess Medical Center, Inc. Methods of treating obesity by inhibiting nicotinamide N-methyl transferase (NNMT)
CA2820885A1 (en) 2010-12-08 2012-09-07 Stem Centrx, Inc. Novel modulators and methods of use
RU2627171C2 (ru) 2010-12-21 2017-08-03 Эббви Инк. Il-1 альфа и бета биспецифические иммуноглобулины с двойными вариабельными доменами и их применение
US20120275996A1 (en) 2010-12-21 2012-11-01 Abbott Laboratories IL-1 Binding Proteins
EP3202903B1 (de) 2010-12-22 2020-02-12 President and Fellows of Harvard College Kontinuierliche gerichtete evolution
JP2014504503A (ja) 2010-12-28 2014-02-24 ゾーマ テクノロジー リミテッド Ｐｄｚドメインを用いた細胞表面提示
WO2012089814A1 (en) 2010-12-30 2012-07-05 INSERM (Institut National de la Santé et de la Recherche Médicale) Antigen binding formats for use in therapeutic treatments or diagnostic assays
EP3187216B1 (de) 2011-01-24 2019-08-21 AbbVie Biotechnology Ltd. Automatische injektionsvorrichtungen mit umspritzten greifflächen
WO2012109238A2 (en) 2011-02-07 2012-08-16 President And Fellows Of Harvard College Methods for increasing immune responses using agents that directly bind to and activate ire-1
SA112330278B1 (ar) 2011-02-18 2015-10-09 ستيم سينتركس، انك. مواد ضابطة جديدة وطرق للاستخدام
MY181093A (en) 2011-03-02 2020-12-17 Berg Llc Interrogatory cell-based assays and uses thereof
AU2012225574A1 (en) 2011-03-07 2013-09-26 University Of Louisville Research Foundation, Inc. Predictive marker of DNMT1 inhibitor therapeutic efficacy and methods of using the marker
WO2012125735A1 (en) 2011-03-15 2012-09-20 Abott Laboratories An integrated approach to the isolation and purification of antibodies
WO2012128810A1 (en) 2011-03-23 2012-09-27 Abbott Laboratories Methods and systems for the analysis of protein samples
KR20140018299A (ko) 2011-03-30 2014-02-12 아블린쓰 엔.브이. Ｔｎｆ-알파에 대한 단일 도메인 항체를 이용하여 면역 장애를 치료하는 방법
WO2012134813A1 (en) 2011-03-31 2012-10-04 St. Jude Children's Research Hospital Methods and compositions for identifying minimal residual disease in acute lymphoblastic leukemia
WO2012139058A1 (en) 2011-04-08 2012-10-11 Biogen Idec Ma Inc. BIOMARKERS PREDICTIVE OF THERAPEUTIC RESPONSIVENESS TO IFNβ AND USES THEREOF
WO2012142164A1 (en) 2011-04-12 2012-10-18 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Human monoclonal antibodies that bind insulin-like growth factor (igf) i and ii
EP2966089B1 (de) 2011-06-02 2020-03-25 Dyax Corp. Fc-rezeptor-bindende proteine
EP2714735B1 (de) 2011-06-03 2021-07-21 XOMA Technology Ltd. Tgf-beta-spezifische antikörper
MX2014000531A (es) 2011-07-13 2014-12-05 Abbvie Inc Metodos y composiciones para el tratamiento del asma usando anticuerpos anti-il-13.
ES2704126T3 (es) 2011-08-23 2019-03-14 Found Medicine Inc Moléculas de fusión KIF5B-RET y usos de las mismas
US20130058947A1 (en) 2011-09-02 2013-03-07 Stem Centrx, Inc Novel Modulators and Methods of Use
WO2013034687A1 (en) 2011-09-09 2013-03-14 Universität Bern Verwaltungsdirektion Avibacterium paragallinarum rtx toxin
CA2848368C (en) 2011-09-13 2023-02-14 Dana-Farber Cancer Institute, Inc. Compositions and methods for brown fat induction and activity using fndc5
EP2771349B1 (de) 2011-09-16 2020-02-26 Iogenetics, LLC. Bioinformatikverfahren zur bestimmung von peptidbindungen
EP3275461A1 (de) 2011-09-19 2018-01-31 Axon Neuroscience SE Proteinbasierte therapie und diagnose von tau-vermittelter pathologie im bereich von morbus alzheimer
CA2851388C (en) 2011-10-10 2023-11-21 The Hospital For Sick Children Methods and compositions for screening and treating developmental disorders
AR088513A1 (es) 2011-10-24 2014-06-18 Abbvie Inc Inmunoenlazantes dirigidos contra esclerostina
WO2013063114A1 (en) 2011-10-24 2013-05-02 Abbvie Inc. Immunobinders directed against tnf
US10527526B2 (en) 2011-11-03 2020-01-07 Tripath Imaging, Inc. Methods and compositions for preparing samples for immunostaining
US11180807B2 (en) 2011-11-04 2021-11-23 Population Bio, Inc. Methods for detecting a genetic variation in attractin-like 1 (ATRNL1) gene in subject with Parkinson's disease
CN104271599A (zh) 2011-11-08 2015-01-07 辉瑞公司 使用抗m-csf抗体治疗炎性疾病的方法
WO2013080050A2 (en) 2011-11-30 2013-06-06 Universitaetsklinikum Erlangen Methods and compositions for determining responsiveness to treatment with a tnf-alpha inhibitor
US10118958B2 (en) 2011-12-14 2018-11-06 AbbVie Deutschland GmbH & Co. KG Composition and method for the diagnosis and treatment of iron-related disorders
CA2855570A1 (en) 2011-12-14 2013-06-20 AbbVie Deutschland GmbH & Co. KG Composition and method for the diagnosis and treatment of iron-related disorders
EP2794657B1 (de) 2011-12-19 2017-10-11 Xoma (Us) Llc Verfahren zur behandlung von akne
BR112014015851A2 (pt) 2011-12-30 2019-09-24 Abbvie Inc proteínas de ligação específicas duplas direcionadas contra il-13 e/ou il-17
ES2676725T3 (es) 2012-01-27 2018-07-24 AbbVie Deutschland GmbH & Co. KG Composición y método para el diagnóstico y el tratamiento de enfermedades asociadas con la degeneración de las neuritas
WO2013120018A1 (en) 2012-02-09 2013-08-15 Population Diagnostics, Inc. Methods and compositions for screening and treating developmental disorders
CA2865404C (en) 2012-02-24 2019-08-27 Stem Centrx, Inc. Dll3-binding antibodies and drug conjugates thereof to treat cancer
BR112014024537A2 (pt) 2012-04-02 2017-08-08 Berg Llc métodos para identificar moduladores de um sistema biológico, de um processo de doença, e de angiogênese
US9181572B2 (en) 2012-04-20 2015-11-10 Abbvie, Inc. Methods to modulate lysine variant distribution
WO2013158279A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Protein purification methods to reduce acidic species
HUE045944T2 (hu) 2012-04-20 2020-02-28 Merus Nv Eljárások és eszközök heterodimerikus IG-szerû molekulák elõállítására
WO2013158275A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Cell culture methods to reduce acidic species
JP2015518829A (ja) 2012-05-14 2015-07-06 バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎ ＭＡ Ｉｎｃ． 運動ニューロンに関する状態の処置のためのｌｉｎｇｏ−２アンタゴニスト
WO2013177115A2 (en) 2012-05-21 2013-11-28 Abbvie Inc. Novel purification of human, humanized, or chimeric antibodies using protein a affinity chromatography
WO2013176754A1 (en) 2012-05-24 2013-11-28 Abbvie Inc. Novel purification of antibodies using hydrophobic interaction chromatography
JP6629069B2 (ja) 2012-06-06 2020-01-15 ゾエティス・エルエルシー イヌ化抗ｎｇｆ抗体およびその方法
US9670276B2 (en) 2012-07-12 2017-06-06 Abbvie Inc. IL-1 binding proteins
EP3613765A1 (de) 2012-08-03 2020-02-26 Dana-Farber Cancer Institute, Inc. Antikörper gegen abstossungs führung molekül b (rgmb)
WO2014039860A2 (en) 2012-09-07 2014-03-13 University Of Louisville Research Foundation, Inc. Compositions and methods for modulating dnmt1 inhibitor activity
DK2895621T3 (da) 2012-09-14 2020-11-30 Population Bio Inc Fremgangsmåder og sammensætning til diagnosticering, prognose og behandling af neurologiske tilstande
CA2922005A1 (en) 2012-09-27 2014-04-03 Population Diagnostics, Inc. Methods and compositions for screening and treating developmental disorders
EP3750560A3 (de) 2012-10-09 2021-03-24 Biogen MA Inc. Kombinationstherapien und deren verwendungen zur behandlung von demyelinisierungserkrankungen
SG11201503412RA (en) 2012-11-01 2015-05-28 Abbvie Inc Anti-vegf/dll4 dual variable domain immunoglobulins and uses thereof
AU2013337277B2 (en) 2012-11-05 2018-03-08 Foundation Medicine, Inc. Novel NTRK1 fusion molecules and uses thereof
WO2014074942A1 (en) 2012-11-08 2014-05-15 Illumina, Inc. Risk variants of alzheimer's disease
WO2014074905A1 (en) 2012-11-08 2014-05-15 Eleven Biotherapeutics, Inc. Il-6 antagonists and uses thereof
PT2928923T (pt) 2012-12-10 2020-03-27 Biogen Ma Inc Anticorpos antígenos 2 de células dendríticas anti-sangue e os seus usos
US9550986B2 (en) 2012-12-21 2017-01-24 Abbvie Inc. High-throughput antibody humanization
US10717965B2 (en) 2013-01-10 2020-07-21 Gloriana Therapeutics, Inc. Mammalian cell culture-produced neublastin antibodies
EP3939614A1 (de) 2013-01-18 2022-01-19 Foundation Medicine, Inc. Verfahren zur behandlung cholangiokarzinom
PL2958944T3 (pl) 2013-02-22 2019-09-30 Abbvie Stemcentrx Llc Koniugaty przeciwciało anty-DLL3-PBD i ich zastosowania
EP2970375A1 (de) 2013-03-14 2016-01-20 AbbVie Inc. Schwach saure zusammensetzungen und verfahren zu ihrer herstellung durch verdrängungschromatografie
BR112015023239A8 (pt) 2013-03-14 2018-04-17 Abbott Lab ensaio de combinação de anticorpo-antígeno de hcv e métodos e composições para uso do mesmo
JP6739329B2 (ja) 2013-03-14 2020-08-12 アボット・ラボラトリーズＡｂｂｏｔｔ Ｌａｂｏｒａｔｏｒｉｅｓ Ｈｃｖコア脂質結合ドメインモノクローナル抗体
CA2926301A1 (en) 2013-03-14 2014-10-02 Abbvie Inc. Low acidic species compositions and methods for producing and using the same
WO2014142882A1 (en) 2013-03-14 2014-09-18 Abbvie Inc. Protein purification using displacement chromatography
MX2015012922A (es) 2013-03-14 2016-04-04 Ren Liu Tratamiento del cancer usando anticuerpos que se unen a grp78 en la superficie celular.
MX2015012824A (es) 2013-03-14 2016-06-24 Abbott Lab Antigenos recombinantes ns3 del vhc y mutantes de los mismos para la deteccion mejorada de anticuerpos.
EP2968508B1 (de) 2013-03-15 2022-04-27 Sanofi Pasteur Biologics, LLC Antikörper gegen clostridium-difficile-toxine und verfahren zur verwendung davon
CN105392801A (zh) 2013-03-15 2016-03-09 比奥根Ma公司 使用抗αvβ5抗体治疗和预防急性肾损伤
CN105324396A (zh) 2013-03-15 2016-02-10 艾伯维公司 针对IL-1β和/或IL-17的双重特异性结合蛋白
US9469686B2 (en) 2013-03-15 2016-10-18 Abbott Laboratories Anti-GP73 monoclonal antibodies and methods of obtaining the same
US9499621B2 (en) 2013-04-08 2016-11-22 Cytodyn, Inc. Felinized antibodies and methods of treating retroviral infections in felines
EP3004877A4 (de) 2013-06-06 2017-04-19 Dana-Farber Cancer Institute, Inc. Zusammensetzungen und verfahren zur identifikation, beurteilung, vorbeugung und behandlung von krebs mit pd-l1-isoformen
JP6581572B2 (ja) 2013-06-07 2019-09-25 デューク ユニバーシティ 補体因子ｈ阻害薬
CA2919477A1 (en) 2013-07-31 2015-02-05 Dana-Farber Cancer Institute, Inc. Compositions and methods for modulating thermogenesis using pth-related and egf-related molecules
DK3036320T3 (da) 2013-08-19 2021-07-12 Biogen Ma Inc Styring af proteinglycosylering ved hjælp af dyrkningsmedietilsætning og cellekulturprocesparametre
JP2016538318A (ja) 2013-08-28 2016-12-08 ステムセントリックス， インコーポレイテッド 新規ｓｅｚ６モジュレーターおよび使用方法
PE20160674A1 (es) 2013-08-28 2016-07-21 Stemcentrx Inc Metodos de conjugacion de anticuerpos especificos de sitio y composiciones
EP3521431A1 (de) 2013-09-25 2019-08-07 Cornell University Verbindungen zur induzierung von antitumorimmunität und verfahren dafür
WO2015048330A2 (en) 2013-09-25 2015-04-02 Biogen Idec Ma Inc. On-column viral inactivation methods
WO2015048312A1 (en) 2013-09-26 2015-04-02 Costim Pharmaceuticals Inc. Methods for treating hematologic cancers
WO2015057939A1 (en) 2013-10-18 2015-04-23 Biogen Idec Ma Inc. Anti-s1p4 antibodies and uses thereof
EP4331590A3 (de) 2013-10-29 2024-04-17 President and Fellows of Harvard College Verfahren und zusammensetzungen zur hemmung von oxidativem stress
US20160272674A1 (en) 2013-11-07 2016-09-22 Abbvie Inc. Isolation and purification of antibodies
EP2891722B1 (de) 2013-11-12 2018-10-10 Population Bio, Inc. Verfahren und Zusammensetzungen zur Diagnose, Prognose und Behandlung von Endometriose
BR112016011046A2 (pt) 2013-11-15 2019-01-29 Centre Nat Rech Scient método para genotipagem, método para a detecção de uma infecção, kit para detectar uma infecção e método para detectar em uma amostra biológica.
EP3077048B1 (de) 2013-12-07 2019-07-17 Case Western Reserve University Zusammensetzungen und verfahren zur behandlung von thrombose
RU2714902C2 (ru) 2013-12-19 2020-02-20 Новартис Аг Химерные рецепторы антигена против мезотелина человека и их применение
WO2015095809A1 (en) 2013-12-20 2015-06-25 Biogen Idec Ma Inc. Use of perfusion seed cultures to improve biopharmaceutical fed-batch production capacity and product quality
WO2015095868A1 (en) 2013-12-20 2015-06-25 Wake Forest University Health Sciences Methods and compositions for increasing protective antibody levels induced by pneumococcal polysaccharide vaccines
EP2960252A1 (de) 2014-06-26 2015-12-30 Institut Pasteur Phospholipase zur Behandlung von Immunosuppression
US10179911B2 (en) 2014-01-20 2019-01-15 President And Fellows Of Harvard College Negative selection and stringency modulation in continuous evolution systems
JOP20200094A1 (ar) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
JOP20200096A1 (ar) 2014-01-31 2017-06-16 Children’S Medical Center Corp جزيئات جسم مضاد لـ tim-3 واستخداماتها
CA3212977A1 (en) 2014-02-11 2015-08-20 Visterra, Inc. Antibody molecules to dengue virus and uses thereof
WO2015127407A1 (en) 2014-02-21 2015-08-27 Stemcentrx, Inc. Anti-dll3 antibodies and drug conjugates for use in melanoma
TWI777174B (zh) 2014-03-14 2022-09-11 瑞士商諾華公司 針對lag-3之抗體分子及其用途
DK3122869T3 (da) 2014-03-24 2019-09-09 Biogen Ma Inc Fremgangsmåder til afhjælpning af glutamindeprivation under pattedyrecellekultur
IL248511B (en) 2014-05-13 2022-07-01 Bavarian Nordic As Combined therapy for the treatment of cancer with a focovirus expressing the antigen and a monoclonal antibody against tim-3
US9416172B2 (en) 2014-06-03 2016-08-16 Xbiotech, Inc. Compositions and methods for treating and preventing Staphylococcus aureus infections
US9777061B2 (en) 2014-07-21 2017-10-03 Novartis Ag Treatment of cancer using a CD33 chimeric antigen receptor
WO2016012623A1 (en) 2014-07-25 2016-01-28 Theravectys Lentiviral vectors for regulated expression of a chimeric antigen receptor molecule
JP6919118B2 (ja) 2014-08-14 2021-08-18 ノバルティス アーゲー ＧＦＲα−４キメラ抗原受容体を用いる癌の治療
BR112017003104A2 (pt) 2014-08-19 2017-12-05 Novartis Ag tratamento de câncer usando um receptor antigênico quimérico anti-cd123
EP3182995B1 (de) 2014-08-19 2019-11-27 Immundiagnostik AG Medikament und vorrichtung zur behandlung von chronischer nierenkrankheit
GB2558326B (en) 2014-09-05 2021-01-20 Population Bio Inc Methods and compositions for inhibiting and treating neurological conditions
MX2017003227A (es) 2014-09-13 2017-12-04 Novartis Ag Terapias de combinacion de inhibidores de alk.
US10450376B2 (en) 2014-09-16 2019-10-22 Symphogen A/S Anti-MET antibodies and compositions
EP3200822B1 (de) 2014-09-30 2021-04-14 Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts Bindungsmoleküle, insbesondere antikörper die sich an l1cam (cd171) binden
ES2774448T3 (es) 2014-10-03 2020-07-21 Novartis Ag Terapias de combinación
TWI716362B (zh) 2014-10-14 2021-01-21 瑞士商諾華公司 針對ｐｄ－ｌ１之抗體分子及其用途
MA41685A (fr) 2014-10-17 2017-08-22 Biogen Ma Inc Supplémentation en cuivre pour la régulation de la glycosylation dans un procédé de culture cellulaire de mammifère
WO2016061460A1 (en) 2014-10-17 2016-04-21 Carnegie Mellon University Enhanced biomolecule detection assays based on tyramide signal amplification and gammapna probes
WO2016077052A2 (en) 2014-10-22 2016-05-19 President And Fellows Of Harvard College Evolution of proteases
MA40864A (fr) 2014-10-31 2017-09-05 Biogen Ma Inc Hypotaurine, gaba, bêta-alanine et choline pour la régulation de l'accumulation de sous-produits résiduaires dans des procédés de culture de cellules mammifères
WO2016073685A1 (en) 2014-11-05 2016-05-12 Annexon, Inc. Humanized anti-complement factor c1q antibodies and uses thereof
WO2016073894A1 (en) 2014-11-07 2016-05-12 Eleven Biotherapeutics, Inc. Therapeutic agents with increased ocular retention
IL251858B (en) 2014-11-07 2022-09-01 Eleven Biotherapeutics Inc Improved il–6 antagonists
US10434177B2 (en) 2014-11-17 2019-10-08 Carnegie Mellon University Activatable two-component photosensitizers
US11033637B2 (en) 2014-11-21 2021-06-15 University Of Maryland, Baltimore Targeted structure-specific particulate delivery systems
WO2016094881A2 (en) 2014-12-11 2016-06-16 Abbvie Inc. Lrp-8 binding proteins
EP3034620A1 (de) 2014-12-17 2016-06-22 Diaxonhit Zusammensetzungen und Verfahren zur Diagnose von Schilddrüsenkrebs
EP3233918A1 (de) 2014-12-19 2017-10-25 Novartis AG Kombinationstherapien
FR3030758A1 (fr) 2014-12-19 2016-06-24 Inst Nat De La Rech Agronomique (Inra) Marqueurs diagnostiques de la maladie de crohn
EP3242893A1 (de) 2015-01-08 2017-11-15 Biogen MA Inc. Lingo-1-antagonisten und verwendungen zur behandlung von demyelinisierungserkrankungen
EP3265491A1 (de) 2015-03-03 2018-01-10 Xoma (Us) Llc Behandlung von postprandialer hyperinsulinämie und hyperglykämie nach bariatrischer chirurgie
US20180042998A1 (en) 2015-03-10 2018-02-15 University Of Massachusetts Targeting gdf6 and bmp signaling for anti-melanoma therapy
ES2820768T3 (es) 2015-04-03 2021-04-22 Xoma Technology Ltd Tratamiento del cáncer usando inhibidores de TGF-beta y PD-1
US11299729B2 (en) 2015-04-17 2022-04-12 President And Fellows Of Harvard College Vector-based mutagenesis system
EP3285811A1 (de) 2015-04-21 2018-02-28 Institut Gustave Roussy Therapeutische verfahren, produkte und zusammensetzungen zur hemmung von znf555
EP3095465A1 (de) 2015-05-19 2016-11-23 U3 Pharma GmbH Kombination von fgfr4-inhibitor und gallensäurekomplexbildner
FR3036287A1 (fr) 2015-05-19 2016-11-25 Univ Bordeaux Traitement et detection des trypanosomes
PE20180193A1 (es) 2015-05-29 2018-01-26 Abbvie Inc Anticuerpos anti-cd40 y sus usos
TW201710286A (zh) 2015-06-15 2017-03-16 艾伯維有限公司 抗ｖｅｇｆ、ｐｄｇｆ及／或其受體之結合蛋白
US10392674B2 (en) 2015-07-22 2019-08-27 President And Fellows Of Harvard College Evolution of site-specific recombinases
US11524983B2 (en) 2015-07-23 2022-12-13 President And Fellows Of Harvard College Evolution of Bt toxins
WO2017019897A1 (en) 2015-07-29 2017-02-02 Novartis Ag Combination therapies comprising antibody molecules to tim-3
SI3317301T1 (sl) 2015-07-29 2021-10-29 Novartis Ag Kombinirane terapije, ki obsegajo molekule protitelesa na LAG-3
WO2017019895A1 (en) 2015-07-30 2017-02-02 President And Fellows Of Harvard College Evolution of talens
EP3331562A2 (de) 2015-08-06 2018-06-13 Xoma (Us) Llc Antikörperfragmente gegen den insulinrezeptor und verwendungen davon zur behandlung von hypoglykämie
EP3341415B1 (de) 2015-08-28 2021-03-24 H. Hoffnabb-La Roche Ag Anti-hypusin-antikörper und verwendungen davon
EP3350220B1 (de) 2015-09-15 2021-05-19 Scholar Rock, Inc. Anti-pro/latentes-myostatin-antikörper und verwendungen davon
US11207393B2 (en) 2015-10-16 2021-12-28 President And Fellows Of Harvard College Regulatory T cell PD-1 modulation for regulating T cell effector immune responses
US20210106661A1 (en) 2015-10-29 2021-04-15 Dana-Farber Cancer Institute, Inc. Methods for identification, assessment, prevention, and treatment of metabolic disorders using pm20d1 and n-lipidated amino acids
WO2017083515A2 (en) 2015-11-10 2017-05-18 Visterra, Inc. Antibody molecule-drug conjugates and uses thereof
CA3006058A1 (en) 2015-11-25 2017-06-01 Visterra, Inc. Antibody molecules to april and uses thereof
CN115109850A (zh) 2015-11-30 2022-09-27 谢彦晖 Akt2在诊断和治疗肿瘤中的用途
KR20180088907A (ko) 2015-12-17 2018-08-07 노파르티스 아게 Pd-1에 대한 항체 분자 및 그의 용도
RU2018125603A (ru) 2015-12-17 2020-01-21 Новартис Аг Комбинация ингибитора с-мет с молекулой антитела к pd-1 и ее применения
CN109071645A (zh) 2016-01-08 2018-12-21 供石公司 抗-原肌生长抑制素/潜伏肌生长抑制素抗体及其使用方法
CN109476731A (zh) 2016-02-29 2019-03-15 基础医药有限公司 治疗癌症的方法
WO2017156500A1 (en) 2016-03-11 2017-09-14 Scholar Rock, Inc. Tgfb1-binding immunoglobulins and use thereof
WO2017160599A1 (en) 2016-03-14 2017-09-21 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Use of cd300b antagonists to treat sepsis and septic shock
ES2831852T3 (es) 2016-03-17 2021-06-09 Univ Oslo Hf Proteínas de fusión que se dirigen a macrófagos asociados a tumores para tratar el cáncer
WO2017165464A1 (en) 2016-03-21 2017-09-28 Elstar Therapeutics, Inc. Multispecific and multifunctional molecules and uses thereof
US20170274076A1 (en) 2016-03-25 2017-09-28 Visterra, Inc. Formulations of antibody molecules to dengue virus
CN109414489B (zh) 2016-04-08 2022-08-16 埃缇健康公司D/B/A泽尔拜尔 网蛋白-1结合抗体及其用途
US20170298119A1 (en) 2016-04-15 2017-10-19 Visterra, Inc. Antibody molecules to zika virus and uses thereof
WO2018005559A1 (en) 2016-06-27 2018-01-04 Juno Therapeutics, Inc. Method of identifying peptide epitopes, molecules that bind such epitopes and related uses
MA45491A (fr) 2016-06-27 2019-05-01 Juno Therapeutics Inc Épitopes à restriction cmh-e, molécules de liaison et procédés et utilisations associés
JP7149257B2 (ja) 2016-07-13 2022-10-06 バイオジェン・エムエイ・インコーポレイテッド Ｌｉｎｇｏ－１アンタゴニストの投与計画及び脱髄障害の処置のための使用
CN110461315A (zh) 2016-07-15 2019-11-15 诺华股份有限公司 使用与激酶抑制剂组合的嵌合抗原受体治疗和预防细胞因子释放综合征
WO2018022479A1 (en) 2016-07-25 2018-02-01 Biogen Ma Inc. Anti-hspa5 (grp78) antibodies and uses thereof
EP3490600A1 (de) 2016-08-01 2019-06-05 Xoma (Us) Llc Parathormon-rezeptor 1 (pth1r)-antikörper und verwendungen davon
RU2019104889A (ru) 2016-08-02 2020-09-04 Вистерра, Инк. Генно-инженерные полипептиды и их применение
EP3515936A1 (de) 2016-09-23 2019-07-31 Elstar Therapeutics, Inc. Multispezifische antikörpermoleküle mit lambda- und kappa- leichtketten
CA3038679A1 (en) 2016-09-28 2018-04-05 Xoma (Us) Llc Antibodies that bind interleukin-2 and uses thereof
MX2019003473A (es) 2016-10-03 2019-10-15 Abbott Lab Metodos mejorados para evaluar el estado de ubiquitin carboxi-terminal hidrolasa l1 (uch-l1) en muestras de pacientes.
US10525083B2 (en) 2016-10-07 2020-01-07 Novartis Ag Nucleic acid molecules encoding chimeric antigen receptors comprising a CD20 binding domain
WO2018071576A1 (en) 2016-10-14 2018-04-19 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Treatment of tumors by inhibition of cd300f
AU2017382367A1 (en) 2016-12-23 2019-06-13 Visterra, Inc. Binding polypeptides and methods of making the same
EP4218817A3 (de) 2017-01-06 2023-09-06 Scholar Rock, Inc. Verfahren zur behandlung von stoffwechselerkrankungen durch hemmung der myostatinaktivierung
JP7157744B2 (ja) 2017-01-06 2022-10-20 スカラー ロック インコーポレイテッド アイソフォーム特異的な、コンテクスト寛容ＴＧＦβ１阻害剤およびその使用
WO2018129395A1 (en) 2017-01-06 2018-07-12 Scholar Rock, Inc. Methods for treating metabolic diseases by inhibiting myostatin activation
US11382983B2 (en) 2017-01-13 2022-07-12 Academia Sinica Reloadable hydrogel system for treating brain conditions
WO2018130660A1 (en) 2017-01-13 2018-07-19 Academia Sinica Reloadable hydrogel system for treating myocardial infarction
US11890319B2 (en) 2017-01-18 2024-02-06 Visterra, Inc. Antibody molecule-drug conjugates and uses thereof
US10240205B2 (en) 2017-02-03 2019-03-26 Population Bio, Inc. Methods for assessing risk of developing a viral disease using a genetic test
WO2018141029A1 (en) 2017-02-06 2018-08-09 Meat & Livestock Australia Limited Immunostimulating compositions and uses therefore
US20200291089A1 (en) 2017-02-16 2020-09-17 Elstar Therapeutics, Inc. Multifunctional molecules comprising a trimeric ligand and uses thereof
EP3589650A1 (de) 2017-03-02 2020-01-08 Novartis AG Manipulierte heterodimere proteine
CA3052513A1 (en) 2017-03-23 2018-09-27 Abbott Laboratories Methods for aiding in the diagnosis and determination of the extent of traumatic brain injury in a human subject using the early biomarker ubiquitin carboxy-terminal hydrolase l1
US20200132673A1 (en) 2017-03-24 2020-04-30 The Regents Of The University Of California Proteoglycan irregularities in abnormal fibroblasts and therapies based therefrom
JP2020515637A (ja) 2017-04-03 2020-05-28 オンコロジー、インコーポレイテッド 免疫腫瘍剤を伴うｐｓ標的化抗体を用いる癌の治療方法
JP2020512825A (ja) 2017-04-12 2020-04-30 ファイザー・インク 条件的親和性を有する抗体およびその使用の方法
JP7344797B2 (ja) 2017-04-15 2023-09-14 アボット・ラボラトリーズ 早期バイオマーカーを使用する、ヒト対象における外傷性脳損傷の、超急性の診断及び決定の一助となるための方法
WO2018195283A1 (en) 2017-04-19 2018-10-25 Elstar Therapeutics, Inc. Multispecific molecules and uses thereof
CA3059769A1 (en) 2017-04-28 2018-11-01 Elstar Therapeutics, Inc. Multispecific molecules comprising a non-immunoglobulin heterodimerization domain and uses thereof
CN110603449A (zh) 2017-04-28 2019-12-20 雅培实验室 用同一人受试者的至少两种样品的早期生物标记物帮助超急性诊断确定创伤性脑损伤的方法
US10865238B1 (en) 2017-05-05 2020-12-15 Duke University Complement factor H antibodies
WO2018215535A1 (en) 2017-05-23 2018-11-29 Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Novel cd73 antibody, preparation and uses thereof
CN110651190A (zh) 2017-05-25 2020-01-03 雅培实验室 用早期生物标记物帮助确定是否对已遭受或可能已遭受头部损伤的人受试者执行成像的方法
AU2018275235A1 (en) 2017-05-30 2019-10-31 Abbott Laboratories Methods for aiding in diagnosing and evaluating a mild traumatic brain injury in a human subject using cardiac troponin I and early biomarkers
WO2018222901A1 (en) 2017-05-31 2018-12-06 Elstar Therapeutics, Inc. Multispecific molecules that bind to myeloproliferative leukemia (mpl) protein and uses thereof
KR20200015717A (ko) 2017-06-09 2020-02-12 프로비던스 헬스 앤드 서비시즈 - 오레곤 암 치료를 위한 인간 종양 반응성 t 세포의 확인을 위한 cd39 및 cd103의 활용
US20200172628A1 (en) 2017-06-22 2020-06-04 Novartis Ag Antibody molecules to cd73 and uses thereof
WO2019005817A2 (en) 2017-06-26 2019-01-03 Bio-Techne Corporation HYBRIDOMIC CLONES, MONOCLONAL ANTIBODIES DIRECTED AGAINST VSIG-4, AND METHODS OF MAKING AND USING SAME
WO2019006007A1 (en) 2017-06-27 2019-01-03 Novartis Ag POSOLOGICAL REGIMES FOR ANTI-TIM3 ANTIBODIES AND USES THEREOF
EP3649474A1 (de) 2017-07-03 2020-05-13 Abbott Laboratories Verbesserte verfahren zur messung von ubiquitin-carboxy-terminalen hydrolase-l1-konzentrationen in blut
US11447809B2 (en) 2017-07-06 2022-09-20 President And Fellows Of Harvard College Evolution of tRNA synthetases
PE20200616A1 (es) 2017-07-14 2020-03-11 Pfizer ANTICUERPOS CONTRA MAdCAM
EP3431496A1 (de) 2017-07-19 2019-01-23 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Anti-isoasp7-amyloid-beta-antikörper und verwendungen davon
CN111163798A (zh) 2017-07-20 2020-05-15 诺华股份有限公司 用于抗lag-3抗体的给药方案及其用途
EP3658583A1 (de) 2017-07-28 2020-06-03 Scholar Rock, Inc. Ltbp-komplex-spezifische inhibitoren von tgf-beta 1 und verwendungen davon
EP3444275A1 (de) 2017-08-16 2019-02-20 Exiris S.r.l. Monoklonaler antikörper anti-fgfr4
WO2019035938A1 (en) 2017-08-16 2019-02-21 Elstar Therapeutics, Inc. MULTISPECIFIC MOLECULES BINDING TO BCMA AND USES THEREOF
US11624130B2 (en) 2017-09-18 2023-04-11 President And Fellows Of Harvard College Continuous evolution for stabilized proteins
BR112020005419A2 (pt) 2017-10-02 2020-09-29 Visterra, Inc. moléculas de anticorpo para cd138 e seus usos
ES2759622T3 (es) 2017-10-02 2020-05-11 Certest Biotec S L Anticuerpos anti-Dps y dispositivos de prueba para la detección de bacterias del género Campylobacter
EP3692370A2 (de) 2017-10-04 2020-08-12 OPKO Pharmaceuticals, LLC Artikel und verfahren zur personalisierten krebstherapie
SG11202003486UA (en) 2017-10-19 2020-05-28 Debiopharm Int Sa Combination product for the treatment of cancer
US20200331975A1 (en) 2017-10-20 2020-10-22 Institut Curie Dap10/12 based cars adapted for rush
WO2019099838A1 (en) 2017-11-16 2019-05-23 Novartis Ag Combination therapies
EP3720881A1 (de) 2017-12-08 2020-10-14 Elstar Therapeutics, Inc. Multispezifische moleküle und verwendungen davon
WO2019112860A1 (en) 2017-12-09 2019-06-13 Abbott Laboratories Methods for aiding in diagnosing and evaluating a traumatic brain injury in a human subject using a combination of gfap and uch-l1
WO2019113525A2 (en) 2017-12-09 2019-06-13 Abbott Laboratories Methods for aiding in the diagnosis and evaluation of a subject who has sustained an orthopedic injury and that has or may have sustained an injury to the head, such as mild traumatic brain injury (tbi), using glial fibrillary acidic protein (gfap) and/or ubiquitin carboxy-terminal hydrolase l1 (uch-l1)
EP3746477A1 (de) 2018-02-02 2020-12-09 Bio-Techne Corporation Verbindungen, die die wechselwirkung von vista und vsig3 modulieren, und verfahren zur herstellung und verwendung
WO2019177690A1 (en) 2018-03-12 2019-09-19 Zoetis Services Llc Anti-ngf antibodies and methods thereof
EP3765516A2 (de) 2018-03-14 2021-01-20 Elstar Therapeutics, Inc. Multifunktionale moleküle und verwendungen davon
US20210238280A1 (en) 2018-03-14 2021-08-05 Elstar Therapeutics, Inc. Multifunctional molecules that bind to calreticulin and uses thereof
WO2019180272A1 (en) 2018-03-23 2019-09-26 Fundación Instituto De Investigación Sanitaria De Santiago De Compostela Anti-leptin affinity reagents for use in the treatment of obesity and other leptin-resistance associated diseases
ES2950740T3 (es) 2018-03-26 2023-10-13 Glycanostics S R O Medios y métodos para el glicoperfilado de una proteína
US20210147547A1 (en) 2018-04-13 2021-05-20 Novartis Ag Dosage Regimens For Anti-Pd-L1 Antibodies And Uses Thereof
AR126019A1 (es) 2018-05-30 2023-09-06 Novartis Ag Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación
WO2019241649A1 (en) 2018-06-14 2019-12-19 President And Fellows Of Harvard College Evolution of cytidine deaminases
US20210238268A1 (en) 2018-06-19 2021-08-05 Atarga, Llc Antibody molecules to complement component 5 and uses thereof
WO2020010250A2 (en) 2018-07-03 2020-01-09 Elstar Therapeutics, Inc. Anti-tcr antibody molecules and uses thereof
WO2020008083A1 (es) 2018-07-05 2020-01-09 Consejo Superior De Investigaciones Científicas Diana terapéutica en receptores de quimiocinas para la selección de compuestos útiles para el tratamiento de procesos patológicos que implican la señalización de quimiocinas
EP3820896A1 (de) 2018-07-11 2021-05-19 Scholar Rock, Inc. Tgfbeta1-inhibitoren und verwendung davon
PT3677278T (pt) 2018-07-11 2022-02-03 Scholar Rock Inc Inibidores seletivos da isoforma tgfbeta1 e sua utilização
JP2021531254A (ja) 2018-07-11 2021-11-18 スカラー ロック インコーポレイテッドScholar Rock, Inc. 高親和性のアイソフォーム選択的ＴＧＦβ１阻害剤、およびその使用
WO2020021465A1 (en) 2018-07-25 2020-01-30 Advanced Accelerator Applications (Italy) S.R.L. Method of treatment of neuroendocrine tumors
SI3625368T1 (sl) 2018-08-08 2023-04-28 Pml Screening, Llc Postopki z genetskim testiranjem za oceno tveganja za razvoj progresivne multifokalne levkoencefalopatije, ki jo povzroča virus John Cunningham
CN113164777A (zh) 2018-09-27 2021-07-23 马伦戈治疗公司 Csf1r/ccr2多特异性抗体
CA3113818A1 (en) 2018-10-05 2020-04-09 Bavarian Nordic A/S Combination therapy for treating cancer with an intravenous administration of a recombinant mva and an immune checkpoint antagonist or agonist
UY38407A (es) 2018-10-15 2020-05-29 Novartis Ag Anticuerpos estabilizadores de trem2
BR112021007765A2 (pt) 2018-10-23 2021-08-03 Scholar Rock, Inc. inibidores seletivos de rgmc e uso dos mesmos
WO2020086408A1 (en) 2018-10-26 2020-04-30 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services A high-yield perfusion-based transient gene expression bioprocess
SG11202104918PA (en) 2018-11-20 2021-06-29 Bavarian Nordic As Therapy for treating cancer with an intratumoral and/or intravenous administration of a recombinant mva encoding 4-1bbl (cd137l) and/or cd40l
CN113195539A (zh) 2018-12-20 2021-07-30 诺华股份有限公司 药物组合
SG11202108099WA (en) 2019-01-30 2021-08-30 Scholar Rock Inc LTBP COMPLEX-SPECIFIC INHIBITORS OF TGFβ AND USES THEREOF
US11738050B2 (en) 2019-02-01 2023-08-29 Regents Of The University Of Minnesota Compounds binding to fibroblast activation protein alpha
EP3693063A1 (de) 2019-02-06 2020-08-12 Diaccurate Verfahren und zusammensetzungen zur behandlung von krebs
EP3696191A1 (de) 2019-02-14 2020-08-19 Fundación Instituto de Investigación contra la Leucemia Josep Carreras (IJC) Car-t-zellen zur behandlung von cd1a-positivem krebs
US10871640B2 (en) 2019-02-15 2020-12-22 Perkinelmer Cellular Technologies Germany Gmbh Methods and systems for automated imaging of three-dimensional objects
JP2022521751A (ja) 2019-02-21 2022-04-12 マレンゴ・セラピューティクス，インコーポレーテッド 抗ｔｃｒ抗体分子およびその使用
JP2022521937A (ja) 2019-02-21 2022-04-13 マレンゴ・セラピューティクス，インコーポレーテッド ＮＫｐ３０に結合する抗体分子およびその使用
JP2022522662A (ja) 2019-02-21 2022-04-20 マレンゴ・セラピューティクス，インコーポレーテッド Ｔ細胞に結合する多機能性分子および自己免疫障害を処置するためのその使用
JP2022521750A (ja) 2019-02-21 2022-04-12 マレンゴ・セラピューティクス，インコーポレーテッド カルレティキュリンに結合する多機能性分子およびその使用
SG11202109061YA (en) 2019-02-21 2021-09-29 Marengo Therapeutics Inc Multifunctional molecules that bind to t cell related cancer cells and uses thereof
SG11202110732XA (en) 2019-03-29 2021-10-28 Atarga Llc Anti fgf23 antibody
EP3983442A2 (de) 2019-06-17 2022-04-20 Visterra, Inc. Humanisierte antikörpermoleküle gegen cd138 und verwendungen davon
CA3147757A1 (en) 2019-07-26 2021-02-04 Visterra, Inc. Interleukin-2 agents and uses thereof
SI4007777T1 (sl) 2019-08-02 2024-03-29 Fundacio De Recerca Clinic Barcelona-Institut D'investigacions Biomediques August Pi I Sunyer (Frcb-Idibaps) Cart-t celice proti bcma za zdravljenje multiplega mieloma
EP4031658A1 (de) 2019-08-07 2022-07-27 DB Biotech, AS Verbesserte meerrettichperoxidase-polypeptide
US20220332799A1 (en) 2019-09-04 2022-10-20 Deutsches Zentrum Für Neurodegenerative Erkrankungen E.V. (Dzne) Herv inhibitors for use in treating tauopathies
EP4031578A1 (de) 2019-09-18 2022-07-27 Novartis AG Entpd2-antikörper, kombinationstherapien und verfahren zur verwendung der antikörper und kombinationstherapien
TW202124446A (zh) 2019-09-18 2021-07-01 瑞士商諾華公司 與ｅｎｔｐｄ２抗體之組合療法
CA3157665A1 (en) 2019-10-21 2021-04-29 Novartis Ag Tim-3 inhibitors and uses thereof
JP2022553293A (ja) 2019-10-21 2022-12-22 ノバルティス アーゲー ベネトクラックスおよびｔｉｍ－３阻害剤を用いた併用療法
EP4061406A1 (de) 2019-11-20 2022-09-28 Bavarian Nordic A/S Rekombinante mva-viren zur intratumoralen und/oder intravenösen verabreichung zur behandlung von krebs
JP2023507190A (ja) 2019-12-20 2023-02-21 ノバルティス アーゲー 増殖性疾患を治療するための抗ＴＧＦβ抗体及びチェックポイント阻害薬の使用
WO2021138407A2 (en) 2020-01-03 2021-07-08 Marengo Therapeutics, Inc. Multifunctional molecules that bind to cd33 and uses thereof
WO2021142448A2 (en) 2020-01-11 2021-07-15 Scholar Rock,Inc. Tgf-beta inhibitors and use thereof
BR112022013733A2 (pt) 2020-01-11 2022-11-01 Scholar Rock Inc Inibidores de tgfbeta e uso dos mesmos
TW202140553A (zh) 2020-01-13 2021-11-01 美商威特拉公司 C5ar1抗體分子及其用途
IL293752A (en) 2020-01-17 2022-08-01 Novartis Ag A combination containing a tim-3 inhibitor and a substance that causes hypomethylation for use in the treatment of myeloplastic syndrome or chronic myelomonocytic leukemia
IL295387A (en) 2020-02-05 2022-10-01 Larimar Therapeutics Inc Peptide-binding proteins and their uses
CN115843255A (zh) 2020-03-11 2023-03-24 约瑟夫卡雷拉斯白血病研究基金会 用于治疗b细胞型急性淋巴细胞白血病（b-all）的cd22靶向部分
WO2021203024A1 (en) 2020-04-03 2021-10-07 Visterra, Inc. Antibody molecule-drug conjugates and uses thereof
CA3180321A1 (en) 2020-04-24 2021-10-28 Marengo Therapeutics, Inc. Multifunctional molecules that bind to t cell related cancer cells and uses thereof
CN116096758A (zh) 2020-05-01 2023-05-09 诺华股份有限公司 工程化免疫球蛋白
US20230167193A1 (en) 2020-05-01 2023-06-01 Novartis Ag Immunoglobulin variants
WO2021239666A1 (en) 2020-05-26 2021-12-02 Diaccurate Therapeutic methods
EP4161653A1 (de) 2020-06-03 2023-04-12 Bionecure Therapeutics, Inc. Trophoblastzelloberflächenantigen-2 (trop-2)-antikörper
CA3187823A1 (en) 2020-06-24 2021-12-30 Visterra, Inc. Antibody molecules to april and uses thereof
WO2022010797A2 (en) 2020-07-07 2022-01-13 Bionecure Therapeutics, Inc. Novel maytansinoids as adc payloads and their use for the treatment of cancer
WO2022026592A2 (en) 2020-07-28 2022-02-03 Celltas Bio, Inc. Antibody molecules to coronavirus and uses thereof
EP4193149A1 (de) 2020-08-04 2023-06-14 Abbott Laboratories Verbesserte verfahren und kits zum nachweis von sars-cov-2-protein in einer probe
GB2616354A (en) 2020-08-26 2023-09-06 Marengo Therapeutics Inc Methods of detecting TRBC1 or TRBC2
EP4204450A2 (de) 2020-08-26 2023-07-05 Marengo Therapeutics, Inc. An calreticulin bindende multifunktionelle moleküle und verwendungen davon
JP2023539645A (ja) 2020-08-26 2023-09-15 マレンゴ・セラピューティクス，インコーポレーテッド Ｎｋｐ３０に結合する抗体分子およびその使用
EP4204021A1 (de) 2020-08-31 2023-07-05 Advanced Accelerator Applications International S.A. Verfahren zur behandlung von psma-exprimierenden krebsarten
WO2022043558A1 (en) 2020-08-31 2022-03-03 Advanced Accelerator Applications International Sa Method of treating psma-expressing cancers
WO2022081718A1 (en) 2020-10-14 2022-04-21 Five Prime Therapeutics, Inc. Anti-c-c chemokine receptor 8 (ccr8) antibodies and methods of use thereof
WO2022115538A1 (en) 2020-11-24 2022-06-02 Bio-Techne Corporation Anti-severe acute respiratory syndrome coronavirus antibodies
US20220170948A1 (en) 2020-12-01 2022-06-02 Abbott Laboratories Use of one or more biomarkers to determine traumatic brain injury (tbi) in a human subject having received a head computerized tomography scan that is negative for a tbi
WO2023102384A1 (en) 2021-11-30 2023-06-08 Abbott Laboratories Use of one or more biomarkers to determine traumatic brain injury (tbi) in a subject having received a head computerized tomography scan that is negative for a tbi
TW202237171A (zh) 2020-12-04 2022-10-01 美商威特拉公司 使用介白素-2藥劑之方法
AU2021401316A1 (en) 2020-12-18 2023-07-06 Kiniksa Pharmaceuticals, Ltd. Protein compositions and methods for producing and using the same
EP4271998A1 (de) 2020-12-30 2023-11-08 Abbott Laboratories Verfahren zur bestimmung des sars-cov-2-antigens und anti-sars-cov-2-antikörpers in einer probe
WO2022153212A1 (en) 2021-01-13 2022-07-21 Axon Neuroscience Se Antibodies neutralizing sars-cov-2
AU2022211021A1 (en) 2021-01-20 2023-08-03 Visterra, Inc. Interleukin-2 mutants and uses thereof
EP4284510A1 (de) 2021-01-29 2023-12-06 Novartis AG Dosierungsschemata für anti-cd73- und anti-enpd2-antikörper und verwendungen davon
WO2022182872A2 (en) 2021-02-24 2022-09-01 Alladapt Immunotherapeutics, Inc. Compositions and methods for identification of cross-reactive allergenic proteins and treatment of allergies
JP2024512305A (ja) 2021-03-03 2024-03-19 ザ ユナイテッド ステイツ オブ アメリカ アズ リプリゼンテッド バイ ザ セクレタリー、デパートメント オブ ヘルス アンド ヒューマン サービシーズ 破骨細胞生成の新規制御因子としてのＬａタンパク質
JP2024511373A (ja) 2021-03-18 2024-03-13 ノバルティス アーゲー がんのためのバイオマーカーおよびその使用
WO2022204581A2 (en) 2021-03-26 2022-09-29 Scholar Rock, Inc. Tgf-beta inhibitors and use thereof
TW202304979A (zh) 2021-04-07 2023-02-01 瑞士商諾華公司 抗ＴＧＦβ抗體及其他治療劑用於治療增殖性疾病之用途
WO2022216993A2 (en) 2021-04-08 2022-10-13 Marengo Therapeutics, Inc. Multifuntional molecules binding to tcr and uses thereof
CA3216320A1 (en) 2021-05-18 2022-11-24 Abbott Laboratories Methods of evaluating brain injury in a pediatric subject
EP4348260A2 (de) 2021-06-03 2024-04-10 Scholar Rock, Inc. Tgf-beta inhibitoren und deren therapeutische verwendung
CA3218590A1 (en) 2021-06-07 2022-12-15 Providence Health & Services - Oregon Cxcr5, pd-1, and icos expressing tumor reactive cd4 t cells and their use
WO2022261183A2 (en) 2021-06-08 2022-12-15 Dana-Farber Cancer Institute, Inc. Compositions and methods for treating and/or identifying an agent for treating intestinal cancers
WO2022266034A1 (en) 2021-06-14 2022-12-22 Abbott Laboratories Methods of diagnosing or aiding in diagnosis of brain injury caused by acoustic energy, electromagnetic energy, an over pressurization wave, and/or blast wind
WO2022271867A1 (en) 2021-06-23 2022-12-29 Scholar Rock, Inc. A myostatin pathway inhibitor in combination with a glp-1 pathway activator for use in treating metabolic disorders
CA3225252A1 (en) 2021-07-14 2023-01-19 Jordan JARJOUR Engineered t cell receptors fused to binding domains from antibodies
AU2022328390A1 (en) 2021-08-10 2024-03-21 Adimab, Llc Anti-gdf15 antibodies, compositions and uses thereof
WO2023025927A1 (en) 2021-08-26 2023-03-02 Glycanostics S.R.O Glycoprotein biomarkers for diagnosing cancer
CA3230038A1 (en) 2021-08-31 2023-03-09 Hongwei Zhang Methods and systems of diagnosing brain injury
IL310815A (en) 2021-09-14 2024-04-01 Glycanostics S R O Glycoprotein biomarkers for breast cancer diagnosis
WO2023044094A1 (en) 2021-09-20 2023-03-23 Alnylam Pharmaceuticals, Inc. Inhibin subunit beta e (inhbe) modulator compositions and methods of use thereof
WO2023044483A2 (en) 2021-09-20 2023-03-23 Voyager Therapeutics, Inc. Compositions and methods for the treatment of her2 positive cancer
AU2022354059A1 (en) 2021-09-30 2024-03-28 Abbott Laboratories Methods and systems of diagnosing brain injury
WO2023069421A1 (en) 2021-10-18 2023-04-27 Byomass Inc. Anti-activin a antibodies, compositions and uses thereof
WO2023092004A1 (en) 2021-11-17 2023-05-25 Voyager Therapeutics, Inc. Compositions and methods for the treatment of tau-related disorders
WO2023097254A1 (en) 2021-11-24 2023-06-01 Visterra, Inc. Engineered antibody molecules to cd138 and uses thereof
WO2023097119A2 (en) 2021-11-29 2023-06-01 Dana-Farber Cancer Institute, Inc. Methods and compositions to modulate riok2
TW202333772A (zh) 2021-12-01 2023-09-01 美商威特拉公司 使用介白素-2藥劑之方法
WO2023114978A1 (en) 2021-12-17 2023-06-22 Abbott Laboratories Systems and methods for determining uch-l1, gfap, and other biomarkers in blood samples
WO2023122213A1 (en) 2021-12-22 2023-06-29 Byomass Inc. Targeting gdf15-gfral pathway cross-reference to related applications
WO2023118508A1 (en) 2021-12-23 2023-06-29 Bavarian Nordic A/S Recombinant mva viruses for intraperitoneal administration for treating cancer
US20230213536A1 (en) 2021-12-28 2023-07-06 Abbott Laboratories Use of biomarkers to determine sub-acute traumatic brain injury (tbi) in a subject having received a head computerized tomography (ct) scan that is negative for a tbi or no head ct scan
WO2023147107A1 (en) 2022-01-31 2023-08-03 Byomass Inc. Myeloproliferative conditions
WO2023150652A1 (en) 2022-02-04 2023-08-10 Abbott Laboratories Lateral flow methods, assays, and devices for detecting the presence or measuring the amount of ubiquitin carboxy-terminal hydrolase l1 and/or glial fibrillary acidic protein in a sample
US20230383010A1 (en) 2022-02-07 2023-11-30 Visterra, Inc. Anti-idiotype antibody molecules and uses thereof
TW202400637A (zh) 2022-04-25 2024-01-01 美商威特拉公司 April之抗體分子及其用途
WO2023220695A2 (en) 2022-05-13 2023-11-16 Voyager Therapeutics, Inc. Compositions and methods for the treatment of her2 positive cancer
EP4296279A1 (de) 2022-06-23 2023-12-27 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Anti-transthyretin(ttr)-bindende proteine und ihre verwendungen
WO2024006876A1 (en) 2022-06-29 2024-01-04 Abbott Laboratories Magnetic point-of-care systems and assays for determining gfap in biological samples
WO2024030976A2 (en) 2022-08-03 2024-02-08 Voyager Therapeutics, Inc. Compositions and methods for crossing the blood brain barrier
WO2024059708A1 (en) 2022-09-15 2024-03-21 Abbott Laboratories Biomarkers and methods for differentiating between mild and supermild traumatic brain injury
WO2024062038A1 (en) 2022-09-21 2024-03-28 Elthera Ag Novel binding molecules binding to l1cam

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE114723T1 (de) * 1987-03-02 1994-12-15 Enzon Lab Inc Organismus als träger für ''single chain antibody domain (scad)''.
AU4308689A (en) * 1988-09-02 1990-04-02 Protein Engineering Corporation Generation and selection of recombinant varied binding proteins
US5427908A (en) * 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
EP0600866B1 (de) * 1990-06-01 1997-12-03 Chiron Corporation Zusammensetzungen und verfahren zur identifizierung von molekülen mit biologischer wirksamkeit
US6172197B1 (en) 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
CA2095633C (en) * 1990-12-03 2003-02-04 Lisa J. Garrard Enrichment method for variant proteins with altered binding properties
DE4122599C2 (de) * 1991-07-08 1993-11-11 Deutsches Krebsforsch Phagemid zum Screenen von Antikörpern

Also Published As

Publication number Publication date
EP0547201A1 (de) 1993-06-23
ES2323444T3 (es) 2009-07-16
DK1065271T3 (da) 2009-06-15
EP2025753B1 (de) 2010-09-15
DE4122599A1 (de) 1993-02-04
US6730483B2 (en) 2004-05-04
ES2352818T3 (es) 2011-02-23
EP1065271B1 (de) 2009-03-25
DE4122599C2 (de) 1993-11-11
EP0547201B1 (de) 2001-03-21
US5849500A (en) 1998-12-15
US6127132A (en) 2000-10-03
DE59210010D1 (de) 2010-10-28
DK2025753T3 (da) 2010-12-13
ATE199936T1 (de) 2001-04-15
ATE481488T1 (de) 2010-10-15
ATE426667T1 (de) 2009-04-15
US5985588A (en) 1999-11-16
WO1993001288A1 (de) 1993-01-21
DE59209896D1 (de) 2001-04-26
DK0547201T3 (da) 2001-07-23
US6387627B1 (en) 2002-05-14
EP2025753A3 (de) 2009-07-08
EP1065271A1 (de) 2001-01-03
JPH06500930A (ja) 1994-01-27
EP2025753A2 (de) 2009-02-18
US20020160463A1 (en) 2002-10-31

Similar Documents

Publication Publication Date Title
ATE426667T1 (de) Phagemid zum screenen von antikírpern
NO885326D0 (no) Human vevfaktor-beslektede dna-segmenter, polypeptider og antistoffer.
DE3855536T2 (de) Rezeptoren für wachstumshormone
ES2073571T3 (es) Aplicacion de nuevos fragmentos de adn como secuencia que codifica un peptido señal para la secrecion de proteinas maduras, mediante levaduras recombinantes, cassettes de expresion, levaduras transformadas y procedimiento correspondiente de preparacion de proteinas.
CH0229046H1 (de) Method for obtaining dna, rna, peptides, polypeptinique. des or proteins by means of a dna recombinant tech
DE69434413D1 (de) Fusionsproteine zwischen antigene aminosäuresequenzen und beta - 2- mikroglobulin
DK166546C (da) Fremgangsmaade til spaltning af peptider og proteiner ved methionyl-bindingen
ES2129487T3 (es) Peptidos sinteticos, anticuerpos dirigidos contra ellos y su utilizacion.
FI863188A (fi) Kombinationsfoerfaranden foer producering av serinproteas-inhibitorer och foer dessa anvaendbara dna-sekvenser.
KR850006550A (ko) 단백질의 제조방법
JPS646219A (en) Peptide having promoting action on activation of protein c by thrombin
DK0901526T3 (da) Cortistatin: neuropeptider, sammensætninger og metoder
ATE389018T1 (de) Cx3c chemokin-gene von säugetieren
WO1998039421A3 (en) Mammalian proteinases; oxidoreductases; gtp binding proteins; related reagents
DE69128039T2 (de) Allergene aus roggenspreupollen
ES2065341T3 (es) Vectores y compuestos para la expresion de formas zimogenas de proteina c humana.
ATE294237T1 (de) S?ugetier thymokingene
ATE78873T1 (de) Verfahren zur selektiven spaltung von fusionsproteinen.
AR002004A1 (es) Proteina slam, anticuerpo o un fragmento del mismo que se fija a dicha proteina, metodo de purificacion, acido nucleico que codifica dicha proteina,vector de expresion, equipo que la contiene, metodo de deteccion, metodo de modulacion y metodo para preparar una composicion farmaceutica.
IL139272A0 (en) New peptide fragments for protein purification
FI870501A (fi) Menetelmä melanoomaan liittyvän p97-antigeenin antigeenisen sukulaispeptidin tai -proteiinin valmistamiseksi, sekä siinä käyttökelpoiset yhdistelmävirukset, yhdistelmävektorit ja isäntäsolut
BR1100350A (pt) Peptìdeo-sinal, sequências de adn codificando para este, vetores de expressão portando uma dessas sequências e processo de produção periplásmica de um polipetìdeo
TH36737A (th) การคัดสรรโปรตีน โดยใช้การเชื่อมต่อระหว่างอาร์เอ็นเอกับโปรตีน

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
R071 Expiry of right

Ref document number: 1065271

Country of ref document: EP